A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2011
03/17/2011	US20110065703 Novel agents of calcium ion channel modulators
03/17/2011	US20110065701 Pharmaceutical compounds
03/17/2011	US20110065700 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
03/17/2011	US20110065699 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
03/17/2011	US20110065697 2-oxy-benzoxazinone derivatives for the treatment of obesity
03/17/2011	US20110065696 Imidazoyl pyridine compounds and salts thereof
03/17/2011	US20110065694 Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof
03/17/2011	US20110065693 Therapeutic pyrazoloquinoline derivatives
03/17/2011	US20110065692 Therapeutic pyrazolonaphthyridine derivatives
03/17/2011	US20110065691 Therapeutic piperazines
03/17/2011	US20110065689 Therapeutic piperazines
03/17/2011	US20110065688 Therapeutic piperazines
03/17/2011	US20110065685 Novel indoles are cannabinoid receptor ligands
03/17/2011	US20110065684 Phthalazine derivatives as parp inhibitors
03/17/2011	US20110065683 Trisubstituted pyrazoles as acetylcholine receptor modulators
03/17/2011	US20110065681 Amide compounds, compositions and uses thereof
03/17/2011	US20110065676 Combination therapies comprising par1 antagonists with nar agonists
03/17/2011	US20110065675 Azo dye related small molecule modulators of protein-protein interactions
03/17/2011	US20110065674 Methods and compositions for improving cognitive function
03/17/2011	US20110065669 Oxazolobenzimidazole derivatives
03/17/2011	US20110065668 Phenylpyrazole derivatives
03/17/2011	US20110065667 Phenylpyrazole derivatives
03/17/2011	US20110065662 Compounds, Compositions, and Methods for Protecting Brain Health in Neurodegenerative Disorders
03/17/2011	US20110065659 Protopanaxadiol-type ginsenoside compositions and uses thereof
03/17/2011	US20110065657 Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
03/17/2011	US20110065656 Dopaminergic mimetics
03/17/2011	US20110065654 Compositions and methods for alzheimer's disease
03/17/2011	US20110065648 Advantageous mu-opiate receptor peptide compounds
03/17/2011	US20110065647 Novel peptides isolated from spider venom, and uses thereof
03/17/2011	US20110065646 Use of a Homeoprotein of the Bicoid Family for Preventing or Treating Retinal Ganglionic Neuron Degeneration
03/17/2011	US20110065645 Compositions and Methods for Modulating Neuron Degeneration and Neuron Guidance
03/17/2011	US20110065643 Clusterin Pharmaceuticals and Treatment Methods Using the Same
03/17/2011	US20110065637 Method to reduce SLOSH energy absorption and its damaging effects through the reduction of inelastic collisions in an organism
03/17/2011	US20110065630 Use of a octreotide as a therapeutic agent
03/17/2011	US20110065628 Medication Combinations for the Treatment of Alcoholism and Drug Addiction
03/17/2011	US20110065627 Transdermal delivery of medicaments with combinations of cetylated fatty fatty ester penetrant complexes
03/17/2011	US20110065187 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
03/17/2011	US20110065186 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
03/17/2011	US20110065180 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
03/17/2011	US20110065147 Methods and reagents for modulating cholesterol levels
03/17/2011	US20110064819 Encapsulation of biologically active agents
03/17/2011	US20110064817 Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients
03/17/2011	US20110064811 Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
03/17/2011	US20110064808 Extended release formulation of levetiracetam
03/17/2011	US20110064807 Extended release formulation of levetiracetam
03/17/2011	US20110064804 Methods and Compositions for the Treatment of CNS-Related Conditions
03/17/2011	US20110064792 Method for Opening Tight Junctions
03/17/2011	US20110064788 Pharmaceutical compositions for treatment of addiction
03/17/2011	US20110064786 Novel use of basic fibroblast growth factor in the de-differentiation of animal connective tissue cells
03/17/2011	US20110064781 Novel heparin entities and methods of use
03/17/2011	US20110064762 Protein a compositions and methods of use
03/17/2011	US20110064757 Nucleic acid molecules and polypeptides for immune modulation
03/17/2011	US20110064750 Method and kit for treating nicotine addiction
03/17/2011	US20110064749 Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
03/17/2011	US20110064744 Prevention and treatment of pain using antibodies to lysophosphatidic acid
03/17/2011	US20110064741 Stable amyloid beta monomers and oligomers
03/17/2011	US20110064734 Prevention and treatment of amyloidogenic disease
03/17/2011	US20110064729 Administration of agents for the treatment of inflammation
03/17/2011	US20110064722 Modulators of alpha-synuclein toxicity
03/17/2011	US20110064721 Cathepsin-d neuroprotection
03/17/2011	US20110064711 Compositions containing coenzyme q-10 and an antioxidant
03/17/2011	US20110064700 Neural stem cells
03/17/2011	US20110064671 Modulation of blood brain barrier permeability
03/17/2011	US20110064669 Use of galanin in a method of treating neurodegenerative diseases or conditions
03/17/2011	US20110064668 J-superfamily conotoxin peptides
03/17/2011	DE19626431B4 Verwendung einer pharmazeutische Komposition mit antialkoholischer und nootroper Wirkung Use of a pharmaceutical composition with anti alcoholic and nootropic effect
03/17/2011	CA2811318A1 Concentration and mental performance amplifying formulation
03/17/2011	CA2774140A1 Vaccines directed to langerhans cells
03/17/2011	CA2773590A1 8-oxodihydropurine derivative
03/17/2011	CA2773523A1 Compositions and methods for enhancing cognitive and related functions in animals
03/17/2011	CA2773340A1 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
03/17/2011	CA2773253A1 Therapeutic agent for chronic pain
03/17/2011	CA2772697A1 Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease
03/17/2011	CA2772525A1 Histamine h3 inverse agonists and antagonists and methods of use thereof
03/17/2011	CA2772522A1 Histamine h3 inverse agonists and antagonists and methods of use thereof
03/17/2011	CA2771885A1 1,2-dihydro-2-oxoquinoline compounds as 5-ht4receptor ligands
03/16/2011	EP2295550A2 Crystal structures of GSK-3beta protein and protein complexes and their use.
03/16/2011	EP2295539A1 Cell fractions containing cells capable of differentiating into neural cells
03/16/2011	EP2295529A2 Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
03/16/2011	EP2295456A1 Albumin fusion proteins
03/16/2011	EP2295454A1 SLO2, a novel potassium channel protein from human brain
03/16/2011	EP2295442A2 Inhibitors of interleukin-1beta converting enzyme
03/16/2011	EP2295437A1 Diazabicyclic central nervous system active agents
03/16/2011	EP2295433A2 JNK inhibitors
03/16/2011	EP2295429A1 3-((hetero)aryl)-indazoles as Liver X receptor (LXR) and Th-1 inhibitors for the treatment of cardiovascular diseases
03/16/2011	EP2295417A1 Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound
03/16/2011	EP2295413A1 Indazole compounds useful as protein kinase inhibitors
03/16/2011	EP2295412A1 Indazole compounds useful as protein kinase inhibitors
03/16/2011	EP2295069A1 Treatment of neurological disorders with haematopoietic growth factors
03/16/2011	EP2295063A2 Compositions and the use thereof the treatment of mitochondrial diseases
03/16/2011	EP2295061A1 Agent for treatment of schizophrenia
03/16/2011	EP2295060A2 Stabilization of hypoxia inducible factor (HIF) alpha
03/16/2011	EP2295059A2 Stabilization of hypoxia inducible factor (HIF) alpha
03/16/2011	EP2295058A1 Depot formulations of iloperidone with a polymer
03/16/2011	EP2295055A2 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
03/16/2011	EP2295050A1 Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
03/16/2011	EP2295049A1 Treatment of autoimmune diseases
03/16/2011	EP2295047A2 Use of adenosine A2a receptor antagonists for the treatment of restless leg syndrome and other movement disorders
03/16/2011	EP2295043A1 Controlled release hydrocodone formulations
03/16/2011	EP2295042A1 Controlled release hydrocodone formulations

1 ... 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 ... 1833